Upgrade for Complete Access See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Boehringer Ingelheim
Dow
Merck
McKesson
Johnson and Johnson

Last Updated: January 29, 2022

DrugPatentWatch Database Preview

Claims for Patent: 8,076,290

➤ Subscribe for complete access

« Back to Dashboard

Summary for Patent: 8,076,290
Title:Stabilizing alkylglycoside compositions and methods thereof
Abstract: The present invention relates to alkylglycoside-containing compositions and methods for increasing the stability, reducing the aggregation and immunogenicity, increasing the biological activity, and reducing or preventing fibrillar formation of a peptide, polypeptide, or variant thereof, for example insulin and Peptide T or analog thereof.
Inventor(s): Maggio; Edward T. (San Diego, CA)
Assignee: Aegis Therapeutics, Inc. (San Diego, CA)
Application Number:11/937,966
Patent Claims:1. A method for increasing the stability of parathyroid hormone (PTH), fragment PTH 1-34, or fragment PTH 3-34 comprising: admixing the parathyroid hormone, fragment PTH 1-34, or fragment PTH 3-34 and a stabilizing agent to form a composition, wherein the stabilizing agent is at least one alkylglycoside surfactant selected from the group consisting of dodecyl maltoside, tridecyl maltoside, tetradecyl maltoside, sucrose mono-dodecanoate, sucrose mono-tridecanoate and sucrose mono-tetradecanoate, thereby increasing the stability of the parathyroid hormone, fragment PTH 1-34, or fragment PTH 3-34.

2. The method of claim 1, wherein the composition further comprises a mucosal delivery-enhancing agent selected from the group consisting of an aggregation inhibitory agent, a charge-modifying agent, a pH control agent, a degradative enzyme inhibitory agent, a mucolytic or mucus clearing agent, a chitosan, and a ciliostatic agent.

3. The method of claim 2, wherein the composition further comprises benzalkonium chloride or chloroethanol.

4. The method of claim 1, wherein the composition further comprises a membrane penetration-enhancing agent selected from the group consisting of a surfactant, a bile salt, a phospholipid additive, a mixed micelle, a liposome, a carrier, an alcohol, an enamine, a nitric oxide donor compound, a long-chain amphipathic molecule, a small hydrophobic penetration enhancer, a sodium or a salicylic acid derivative, a glycerol ester of acetoacetic acid, a cyclodextrin or beta-cyclodextrin derivative, a medium-chain fatty acid, a chelating agent, an amino acid or salt thereof, an N-acetylamino acid or salt thereof, an enzyme degradative to a selected membrane component and any combination thereof.

5. The method of claim 1, wherein the composition further comprises a modulatory agent of epithelial junction physiology.

6. The method of claim 1, wherein the method further comprises lyophilizing the composition.

7. The method of claim 6, wherein the composition retains greater than 50% biological activity upon reconstitution.

8. The method of claim 1, wherein the composition is stable for at least one month when stored at temperatures from about 25 to 37 degrees Celsius.

9. The method of claim 1, wherein the composition is stable for at least one year when stored at about 4 degrees Celsius.

10. The method of claim 1, wherein the stability of the composition is determined by determining the bioactivity of the parathyroid hormone (PTH), fragment PTH 1-34, or fragment PTH 3-34 in an in vivo or in vitro assay.

11. The method of claim 1, wherein the composition further comprises a bulking agent selected from the group consisting of albumin, collagen, alginate, and mannitol.

12. The method of claim 6, wherein the composition is reconstituted.

13. A method for reducing aggregation of a parathyroid hormone (PTH), fragment PTH 1-34, or fragment PTH 3-34 comprising: admixing the parathyroid hormone (PTH), fragment PTH 1-34, or fragment PTH 3-34 and an aggregation reducing agent, wherein the aggregation reducing agent is at least one alkylglycoside surfactant selected from the group consisting of dodecyl maltoside, tridecyl maltoside, tetradecyl maltoside, sucrose mono-dodecanoate, sucrose mono-tridecanoate and sucrose mono-tetradecanoate, thereby reducing aggregation of the parathyroid hormone (PTH), fragment PTH 1-34, or fragment PTH 3-34.

14. A method for reducing immunogenicity of a parathyroid hormone (PTH), or fragment PTH 1-34, or fragment PTH 3-34 upon administration to a vertebrate, comprising: a) admixing a parathyroid hormone (PTH), or fragment PTH 1-34, or fragment PTH 3-34 and an immunogenicity reducing agent to form a composition, wherein the immunogenicity reducing agent is at least one alkylglycoside surfactant selected from the group consisting of dodecyl maltoside, tridecyl maltoside, tetradecyl maltoside, sucrose mono-dodecanoate, sucrose mono-tridecanoate and sucrose mono-tetradecanoate; and b) administering the composition to a vertebrate thereby reducing immunogenicity upon administration of the parathyroid hormone (PTH), or fragment PTH 1-34, or fragment PTH 3-34.

15. A method of manufacturing a non-aggregated aqueous solution of a parathyroid hormone (PTH), or fragment PTH 1-34, or fragment PTH 3-34 comprising: admixing the parathyroid hormone (PTH), or fragment PTH 1-34, or fragment PTH 3-34 and at least one alkylglycoside surfactant to form an aqueous solution, wherein the surfactant is selected from the group consisting of dodecyl maltoside, tridecyl maltoside, tetradecyl maltoside, sucrose mono-dodecanoate, sucrose mono-tridecanoate and sucrose mono-tetradecanoate, thereby manufacturing the non-aggregated aqueous solution.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Merck
Dow
Mallinckrodt
Harvard Business School
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.